Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia
Tóm tắt
The aim of this study was to investigate the prognostic significance of the absolute natural killer (NK) cell counts in peripheral blood in patients with chronic lymphocytic leukemia (CLL). A total of 273 previously untreated patients with CLL from April 2004 and October 2015 were enrolled into this retrospective study. We analysed the T cell subsets of all patients and figured out the number of NK cells. Comparisons of NK cell count as continuous parameter in different groups were described using Mann–Whitney U test and the Kruskal–Wallis test. Kaplan–Meier method was used to survival analysis, and the Cox proportional hazards models were used for the estimation of prognostic factors. NK cell counts were calculated in 273 therapy-naive CLL patients, and higher number of NK cell was observed in those with Binet stage A/B, ZAP-70 < 20%, normal serum albumin and β2-microglobulin levels. Using a NK cell count cut-off of 0.40 × 109/L, patients with lower NK cell count (< 0.40 × 109/L) had a significantly shorter overall survival (OS) than those with higher NK cell count (≥ 0.40 × 109/L) (P = 0.0014). Multivariate analysis showed that NK cell counts remained its prognostic value. However, the effect of NK cell count on time to treatment was not significant. Our results suggest that NK cell count is an independent prognostic marker for OS in patients with CLL and NK cell counts ≥ 0.40 × 109/L can routinely be used to identify patients with favorable survival.
Tài liệu tham khảo
Binet JL, Auquier A, Dighiero G et al (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198–206
Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10:7252–7259
Chen L, Zhang Y, Zheng W et al (2008) Distinctive IgVH gene segments usage and mutation status in Chinese patients with chronic lymphocytic leukemia. Leuk Res 32:1491–1498
Chen CI, Bergsagel PL, Paul H et al (2011) Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 29:1175–1181
Costello RT, Knoblauch B, Sanchez C et al (2012) Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia. Immunology 135:151–157
Cvetković RS, Perry CM (2006) Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 66:791–820
Eichhorst B, Robak T, Montserrat E et al (2015) Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v78–84
Ferrajoli A, Lee BN, Schlette EJ et al (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111:5291–5297
Foa R, Del Giudice I, Guarini A et al (2013) Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica 98:675–685
Galustian C, Meyer B, Labarthe M-C et al (2008) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58:1033–1045
Hayashi T, Hideshima T, Akiyama M et al (2005) Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 128:192–203
Huang B, Sikorski R, Sampath P, Thorne SH (2011) Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer. J Immunother 34:289–296
Huergo-Zapico L, Acebes-Huerta A, Gonzalez-Rodriguez AP et al (2014) Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease. PLoS ONE 9:e108326
Huntington ND, Vosshenrich CAJ, Di Santo JP (2007) Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 7:703–714
Kay NE, Zarling JM (1984) Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 63:305–309
Laprevotte E, Voisin G, Ysebaert L et al (2013) Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy. J Immunol 191:3634–3640
Liu L, Chen B, Qin S et al (2010) A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells. Biochem Biophys Res Commun 392:190–195
MacFarlane AW, Jillab M, Smith MR et al (2017) NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors. Oncoimmunology 6:e1330235
Ning Z-Q, Li Z-B, Newman MJ et al (2011) Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol 69:901–909
Nückel H, Rebmann V, Dürig J et al (2005) HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 105:1694–1698
Palmer S, Hanson CA, Zent CS et al (2008) Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol 141:607–614
Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46(2):219–234
Rizzo R, Audrito V, Vacca P et al (2014) HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 bp (rs66554220) polymorphism. Haematologica 99:888–896
Romagnani C (2013) Signatures of human NK cell development and terminal differentiation. Front Immunol 4:1–6
Sarah T (2015) XVI international workshop on chronic lymphocytic leukemia 2015 6–9 September 2015 Sydney, Australia. Leuk Lymphoma 56:1–166
Shi Y, Dong M, Hong X et al (2015) Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26:1766–1771
Spits H, Artis D, Colonna M et al (2013) Innate lymphoid cells–a proposal for uniform nomenclature. Nat Rev Immunol 13:145–149
Veuillen C, Aurran-Schleinitz T, Castellano R et al (2012) Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. J Clin Immunol 32:632–646
Weiner GJ (2010) Rituximab: mechanism of action. Semin Hematol 47:115–123
Własiuk P, Tomczak W, Zając M et al (2013) Total expression of HLA-G and TLR-9 in chronic lymphocytic leukemia patients. Hum Immunol 74:1592–1597
Xu W, Li J-Y, Wu Y-J et al (2008) Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia. Leuk Res 32:1071–1077
Xu W, Li J-Y, Wu Y-J et al (2009) CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia. Leuk Res 33:237–243
Yu J, Freud AG, Caligiuri MA (2013) Location and cellular stages of natural killer cell development. Trends Immunol 34:573–582